United Therapeutics | Sustainability Performance
Develops pharmaceuticals and medical technologies, focusing on treatments for rare diseases.
1996
United States
1,001 - 5,000 employees
Pharmaceuticals
$1B - 10B in revenue
$1B - 10B in profitability
Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.
Sustainability Ranking & Industry Benchmark
#5087
Overallⓘ#1145
in United Statesⓘ#108
in PharmaceuticalsⓘSustainability Maturity
ⓘSustainability Intent
ⓘOverview
Environmental
Water ManagementNature and biodiversitySocial
Diversity and InclusionPay GapsExternalitiesGovernance
SDG ImpactFinancial Data
Business performanceCapital & innovationAnalyst projections
Aligned
Leading
Intensity
Water consumption intensity (m³ /$M)
Industry Benchmark
82.2
B/M 121.5
Powered by illuminem and GIST Impact
Controversy level
- United Therapeutics Corporation, US pulmonary arterial hypertension biotech, has faced sustained US DOJ scrutiny including the historic 2017 USD 210 million False Claims Act settlement over alleged inadequate co-payment assistance practices, plus the contested 2024 sustained share price volatility amid generic competition affecting institutional shareholders.
Sustainability employees
ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.Total sustainability employees
11+
ⓘThis value represents the estimated number of employees in a company with sustainability-related roles or job titles, as determined by Illuminem using publicly available data.